Treatment of Myasthenia Gravis (MG) Focusing on Corticosteroid Dose: An Insurance Claims Database Study in Japa
Not Applicable
- Conditions
- Myasthenia Gravis
- Registration Number
- JPRN-UMIN000051155
- Lead Sponsor
- CB Japan Co.,Ltd.
- Brief Summary
1. Only about half of MG patients had OCS as an initial treatment and percentages were similar before and after 2014. 2. Achievement rates of OCS below 5mg/day were higher after 2014 than before 2014. 3. Lower doses of OCS (below 5mg/day) were more frequently observed after 2014 than before 2014 in the first 12 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria will be as described below. - Having any immunotherapy for longer than 90 days during the baseline period until 90 days before the index date - Having a claim with MG treatment recorded any time until 90 days before the index date
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main outcomes are as described below. - Achievement of < 5mg/day oral corticosteroid - Time to achieve < 5mg/day oral corticosteroid - Implementation of Early Fast-acting Treatment
- Secondary Outcome Measures
Name Time Method Secondary outcomes are as described below. - Steroid-related complications, including diabetes mellitus, osteoporosis) - Total number of medical procedures performed after the index date - Percentage change in annual total MG-related costs before and after the index date